Informações:
Falhas:
ID
26604
Descrição
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00846027
Link
https://clinicaltrials.gov/show/NCT00846027
Palavras-chave
Versões (1)
- 21/10/2017 21/10/2017 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
21 de outubro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00846027
Eligibility Breast Cancer NCT00846027
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00846027
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Gender | Age
Item
female patients, ≥ 18 years of age.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Breast Carcinoma | Measurable Disease | Lesion Recurrent Local | Metastatic Lesion | Secondary malignant neoplasm of bone
Item
breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastasis only.
boolean
C0678222 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
C0221198 (UMLS CUI [3,1])
C2945760 (UMLS CUI [3,2])
C0205276 (UMLS CUI [3,3])
C1513183 (UMLS CUI [4])
C0153690 (UMLS CUI [5])
C1513041 (UMLS CUI [2])
C0221198 (UMLS CUI [3,1])
C2945760 (UMLS CUI [3,2])
C0205276 (UMLS CUI [3,3])
C1513183 (UMLS CUI [4])
C0153690 (UMLS CUI [5])
Disease HER2 negative
Item
her-2 negative disease.
boolean
C0012634 (UMLS CUI [1,1])
C4087376 (UMLS CUI [1,2])
C4087376 (UMLS CUI [1,2])
Indication Chemotherapy
Item
candidates for chemotherapy.
boolean
C3146298 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status ≤ 2.
boolean
C1520224 (UMLS CUI [1])
Chemotherapy Secondary malignant neoplasm of female breast | Chemotherapy Locally advanced breast cancer
Item
previous chemotherapy for metastatic or locally advanced breast cancer.
boolean
C0392920 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C3495949 (UMLS CUI [2,2])
C0346993 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C3495949 (UMLS CUI [2,2])
Therapeutic radiology procedure Secondary malignant neoplasm of female breast
Item
previous radiotherapy for treatment of metastatic breast cancer.
boolean
C1522449 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,2])
Anthracyclines Adjuvant therapy Completed
Item
any prior adjuvant treatment with anthracyclines completed < 6 months prior to enrollment.
boolean
C0282564 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0677850 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Adrenal Cortex Hormones chronic U/day | Aspirin chronic U/day | Clopidogrel chronic U/day
Item
chronic daily treatment with corticosteroids (≥ 10 mg/day), aspirin (> 325 mg/day) or clopidogrel (> 75mg/day).
boolean
C0001617 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0004057 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0070166 (UMLS CUI [3,1])
C0205191 (UMLS CUI [3,2])
C0456683 (UMLS CUI [3,3])
C0205191 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0004057 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0070166 (UMLS CUI [3,1])
C0205191 (UMLS CUI [3,2])
C0456683 (UMLS CUI [3,3])